Shots: BehaVR to receive $5M up front, ~$18M in development milestone and R&D support along with commercial & operational support fees and is eligible to receive $140M in milestone upon […]readmore
Tags : CNS Disorders
Shots: Alnylam & Regeneron to co-discover RNAi therapies for eye and CNS diseases. Alnylam to receive $400M upfront, $400M equity at a price of $90/share, $200M as milestones and royalties […]readmore
Shots: The FDA’s BT Designation is based on P-II study assessing SAGE-217 vs PBO in 89 patients with moderate to severe major depressive disorder (MDD) The P-II study results: met […]readmore